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Laura van Dussen1, Marieke Biegstraaten1, Carla EM Hollak1 and Marcel GW Dijkgraaf2*Abstract
Objective: To evaluate the cost-effectiveness of enzyme replacement therapy (ERT) compared to standard
medical care without ERT in the Dutch cohort of patients with type 1 Gaucher disease (GD I).
Design: Cost-effectiveness analysis was performed using a life-time state-transition model of the disease’s
natural course. Transition probabilities, effectiveness data and costs were derived from retrospective data and
prospective follow-up of the Dutch study cohort.
Setting: The tertiary referral center for Gaucher disease in the Netherlands.
Participants: The Dutch cohort of patients with GD I.
Intervention: ERT versus standard medical care without ERT in symptomatic patients.
Main outcome measures: Years free of end organ damage (YFEOD) (splenectomy, bone complication, malignancy,
multiple complications), quality adjusted life years (QALY), and costs.
Results: Over an 85 year lifetime, an untreated GD I patient will generate 48.9 YFEOD and 55.86 QALYs. Starting ERT
in a symptomatic patient increases the YFEOD by 12.8 years, while the number of QALYs gained increases by 6.27.
The average yearly ERT medication costs range between €124,000 and €258,000 per patient. The lifetime costs of
ERT starting in the symptomatic stage are €5,716,473 against €171,780 without ERT, a difference of €5,544,693.
Consequently, the extra costs per additional YFEOD or per additional QALY are €434,416 and €884,994 respectively.
After discounting effects by 1.5% and costs by 4% and under a reasonable scenario of ERT unit cost reduction by
25%, these incremental cost-effectiveness ratios could decrease to €149,857 and €324,812 respectively.
Discussion: ERT is a highly potential drug for GD I with substantial health gains. The conservatively estimated
incremental cost-effectiveness ratios are substantially lower than for Pompe and Fabry disease. We suggest that the
high effectiveness has contributed importantly to acceptance of reimbursement of ERT for GD I. The present study
may further support discussions on acceptable price limits for ultra-orphan products.Introduction
Orphan or rare diseases are life threatening or chronic-
ally debilitating, complex conditions with a prevalence
of < 5 per 10.000. Over the last years, the interest of
pharmaceutical companies in these disorders has grown,
due to new legislation related to orphan drug develop-
ment implemented in the US in 1983 and in Europe in
1999. New medications for orphan diseases, including
many inherited metabolic disorders, have been devel-
oped. Clinical evaluation of newly developed products is* Correspondence: m.g.dijkgraaf@amc.uva.nl
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article, unless otherwise stated.sometimes difficult due to scarce knowledge and limited
size of patients groups. Because of time constraints, tri-
als often make use of surrogate endpoints that are not
always clearly related to “hard” clinical endpoints such
as death or the occurrence of serious complications that
interfere with quality of life. As a consequence products
are usually registered under ‘exceptional circumstances’,
which implies that it is accepted that comprehensive
data are unlikely to become available due to the rarity of
the disorder.
Gaucher disease (GD; OMIM#230800), a very rare
disorder with a prevalence of around 1 in 70.000, is a
lysosomal storage disorder that results from defective ac-
tivity of the lysosomal enzyme glucocerebrosidase (or acidntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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macrophages gives rise to hepatosplenomegaly, severely
debilitating bone disease and, in rare cases, central ner-
vous system involvement [1]. Three types of GD have
been described. Type I GD (GD I) is the most common
phenotype, and can be distinguished from the more severe
types II and III GD based on the absence of the typical
neurologic manifestations associated with the latter two
forms [1,2]. Long term complications and associated
conditions of GD I include splenectomy, persisting bone
complications, pulmonary hypertension [3], Parkinson dis-
ease [4] and an increased risk of associated malignancies
including multiple myeloma (MM) and hepatocellular
carcinoma (HCC) [5,6].
Gaucher disease is the first disorder for which purified
enzyme, administered intravenously, has shown to be
effective in reversing most of the symptoms. Currently,
three recombinant enzymes are available (imiglucerase,
Cerezyme®, Genzyme Corporation, Cambridge, MA, USA;
velaglucerase alfa, VPRIV®, Shire Human Genetic Therapies,
MA, USA; and taliglucerase alfa, Protalix Biotherapeutics,
Carmiel, Israel), of which imiglucerase was approved by the
authorities already in the nineties while the latter two have
only recently received approval (taliglucerase in the USA
only). An alternative treatment option is substrate reduction
therapy (SRT). The authorized compound is miglustat
(Zavesca, Actelion Pharmaceutical, Switzerland). However,
it is not the first choice treatment for GD I since it is only
indicated for the treatment of mildly to moderately affected
GD I patients for whom ERT is unsuitable.
Although imiglucerase is not authorized within the EU
as an orphan drug, simply because the European orphan
drug act was installed at a later stage, the questions with
regard to long term outcome of this enzyme therapy and
cost-effectiveness are not different compared to other
orphan diseases, such as Fabry and Pompe disease [7].
In a recent paper we showed that long term enzyme
replacement therapy for Gaucher disease can effectively
reduce the incidence of splenectomy and bone compli-
cations, and will most likely result in a reduction in the
risk of developing malignancies (van Dussen L, Biegstraaten
M, Dijkgraaf MG, Hollak CE: Modelling Gaucher disease
progression: long term enzyme replacement therapy re-
duces the incidence of splenectomy and bone complica-
tions. Submitted). The high cost of this treatment has
been the subject of debates in the past and has set the
benchmark for similar enzyme replacement therapies. A
2001 commentary by Clarke et al illustrates the debate on
payment for ERT for GD in Ontario, Canada [8]. The
increasing impacts on healthcare budgets of the growing
number of orphan medicinal products have resulted in an
increasing interest in health economic evaluations [9]. So
far, for ERT in GD I, only limited cost-effectiveness and
cost-utility analyses have been performed. Connock et alhave reviewed the available data, primarily based on
available literature as well as limited data from the
Gaucher Registry [10]. Without the possibility for complex
modeling, a comparison was made of cost-effectiveness of
enzyme therapy versus no specific treatment for patients
with GD I and a comparison of different dosage regimens.
A literature review identified three studies that reported
economic evaluations all of which produced very high
incremental cost-effectiveness ratios even when high
estimates of effectiveness were assumed. Even when the
most generous assumptions about potential in cost sav-
ings are applied, the incremental cost effectiveness ratio
(ICER) still exceeds £200,000 per quality adjusted life-year
(QALY). However, it was acknowledged that no consi-
deration was given to initiation of treatment in patients at
different stages of disease, effect of immune reaction,
adherence and drug holidays, comparative treatment
effects and the potential for preventing more serious man-
ifestations [10]. A more recent study from the UK Health
Technology Assessment programme calculated that the
minimal additional discounted QALYs needed for each
year on ERT, in order for ERT to be judged as cost-
effective, ranged between 4.2 and 4.8 for adults (assuming
a willingness to pay per QALY of £30,000) [11].
In this paper, we modeled disease progression to assess
the cost-effectiveness of ERT treatment for GD versus
standard medical care without ERT in symptomatic
patients from a societal perspective. The costs per year
free of end-organ damage (YFEOD) were the primary
outcome measure for the cost-effectiveness analysis. The
costs per QALY were the primary outcome measure for
the cost-utility analysis.
Methods
This study was part of the TIPharma project T6-208:
Sustainable Orphan Drug Development through Registries
and Monitoring. Ethical approval was requested at the
institutional review board, METC AMC. The institu-
tional review board stated that ethical approval was
not required.
Markov model structure
A Markov state-transition model was built, in which
different (consecutive) phases of Gaucher disease were
distinguished. The model was built in DATA (Decision
Analysis by Treeage) 3.5 and run in DATA Pro.
Eight mutually exclusive disease states were included:
asymptomatic, signs/symptoms (any mention of signs/
symptoms, organomegaly and/or cytopenia), recovery
(recovery was only possible for patients in the signs/
symptomatic disease state since bone complications and
splenectomy are irreversible), splenectomy, bone compli-
cation (defined as one single bone complication), multiple
complications (defined as multiple bone complications or
Figure 1 The Markov state-transition model of Gaucher disease.
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Parkinson disease or pulmonary hypertension), malignancy
(defined as multiple myeloma/amyloidosis or hepatocellu-
lar carcinoma), and finally, the state of death.
Bone complications and malignancies were defined as
distinctive complications/associated conditions because
it was assumed that these disease manifestations had the
most important impact on quality of life and health care
and non-health care costs. Splenectomy was defined as a
complication of GD I since it is performed in case of
severe splenomegaly and/or cytopenia, and has been
reported to be a risk factor for the occurrence of bone
complications as well as certain GD I -associated malig-
nancies. Further descriptive details of the disease states
are reported in Table S1A of the Gaucher Model Appendix
(provided as Additional file 1).
The Markov state-transition model is designed to
depict the prevalence and progression of disease signs/
symptoms and complications in a simulated cohort of
patients with GD I. During their lifetime patients pro-
gress through the successive disease states according to
Figure 1. The cycle length of this Markov model repre-
sents 1year of life.
Model data sources and assumptions
The model as proposed was developed with data from
the Dutch Gaucher registry, validated with literature
data and evaluated by expert opinion.
The Academic Medical Center is a national referral
center for patients with GD I. This cohort consisted of
all registered GD I patients in the Netherlands with a
definite diagnosis of GD I based upon analysis of enzym-
atic activity and mutation analysis. Historical data were
collected from all patients for whom a medical record
before ERT was available (April 1991). For all patients
who started ERT in the Netherlands after April 1991, data
were collected prospectively up to September 1, 2011.
A natural history cohort and an enzyme replacement
therapy (ERT) cohort were defined as discussed in a
companion paper on long term enzyme replacement
therapy for Gaucher disease (van Dussen L, Biegstraaten
M, Dijkgraaf MG, Hollak CE: Modelling Gaucher disease
progression: long term enzyme replacement therapy
reduces the incidence of splenectomy and bone compli-
cations. Submitted).
Considering data availability, the limited patient number,
and the potential of unwelcome confounding by indi-
cation when contrasting the treatment and no treatment
situations, we made several assumptions:
 state-transition probabilities for the natural course
of GD I are only valid, when based on the period
prior to the introduction of ERT therapy in the
Netherlands; ERT allows for recovery from signs/symptoms;
otherwise, it only affects the probability of
progressing to the next disease state;
 health utilities for treated and untreated patients
are similar as long as the patients are in the same
disease state;
 health care volumes and related costs for treated
and untreated patients are similar as long as they
are in the same disease state, except for the costs
of ERT medication.
Transition probabilities
The time from one disease state to the next state was
estimated by using Kaplan-Meier analysis and corrected
for competing risks according to Ludbrook et al. [12]. It
was estimated when 50% of the cohort in a certain dis-
ease state had reached the next state. Then, the yearly
transition probability was calculated by dividing the
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followed by a correction for the conditional nature of
transition probabilities in the cyclic Markov model with
a lifetime horizon (the Markov Correction factor [13]. If
less than 50% of the cohort reached the next state, then
time and cumulative proportion from the survival curve
were used, where 4 patients were still at risk.
Transition probabilities were calculated for two differ-
ent scenarios. In the base case, it was assumed that ERT
will be offered to new patients as soon as they present
themselves with signs/symptoms of GD I. Alternatively,
we considered a historical perspective by taking the dis-
tribution of patients over the different disease states
when ERT was introduced in the Netherlands in the year
1991 as the starting point. If Dutch GD I patients will
continue to have access to ERT in the future, then the
historical scenario will gradually convert into the base
casea.
All yearly transition probabilities were assumed to be
beta-distributed and are reported in Additional file 1:
Tables S1B-1 (no ERT), S1B-2 (ERT, base case scenario)
and S1B-3 (ERT, historical perspective) of the Additional
file 1: Gaucher Model Appendix. Further details concern-
ing the conceptualization and validation of the model
structure and rates of disease progression are provided in
the Additional file 1: Gaucher model Appendix as well.
Mortality
For the mortality rate the background mortality in the
healthy population was used based on the yearly survival
rates (1-probability of survival) most recently published
by Statistics Netherlands (Centraal Bureau voor de Sta-
tistiek: CBS.nl/en-GB/menu/home/default.htm, survival
tables as of August 11, 2011), with the exception of the
mortality rate for patients with a malignancy since the
mortality rate is higher as compared to the background
mortality.
Health outcomes
Years free of end organ damage were calculated as the
time in years spent in the asymptomatic, signs/symp-
tomatic and recovery disease states.
Data on health status were obtained quarterly with the
EQ-5D quality of life questionnaire. Previous research
had determined the utility of each observed health score
profile on the EQ-5D based on the time trade-off elicit-
ation technique during interviews with adults from the
UK general population [14]. Utilities range from minus
0.594, indicating serious health problems with mobility,
self-care, usual activities, pain/discomfort, and mood, to
unity, indicating no problems at all. By convention,
death takes the value of zero. The resulting health
utilities were averaged per patient per disease state - in-
dependently from therapy status -, and subsequently, perdisease state over patients. Given the cycle length of one
year in the Markov model, these mean health utilities
equaled the number of QALYs generated during a single
model cycle. Table 1 shows the mean health utilities per
year along with their 95% confidence intervals after bias
corrected and accelerated bootstrapping. Also reported
in Table 1 are the mean yearly health utilities by disease
state calculated with a Dutch equivalent of the UK-based
health status scoring algorithm, which originated from a
replication study by Lamers and colleagues [15]. The
impact of applying the Dutch rather than the UK based
general population preferences was addressed in a scenario
analysis.
Health care volume and costs
Our approach to determine health care volume and
costs mimics the approach in an earlier study on the
cost-effectiveness for Fabry [7]. Health care costs inclu-
ded the direct and indirect medical costs of health care
use as well as the indirect non-medical costs of produc-
tion loss. Direct non-medical costs of private help, travel
costs and non-reimbursed out-of-the-pocket expenses
were not taken into consideration because of their
expected relatively low impact. We assume that ERT
would result in a reduction of these costs. Use and fre-
quency of AMC care were collected from the 2004-2011
AMC hospital database based on the patient identifica-
tion code. These data were linked to the available real
unit costs from the AMC hospital ledger to arrive at the
AMC costs [18]. Use and frequency of hospital care out-
side the AMC, out-of-hospital care and production loss
in this patient population were derived from the quar-
terly disseminated Health and Labour questionnaires
during the period May 2009 and April 2011. Subse-
quently these volumes were linked to unit costs from
the Dutch costing manual 2010 for health care research
[19]. The unit costs used were price-indexed for the year
2009 and are presented in Table 2.
The mean yearly ERT costs per patient per disease state
were determined by (i) averaging the number of vials of
400 IU per month per disease state (weighted by the
lengths of dose-specific episodes during the disease state)
for each patient, (ii) averaging these mean numbers of
vials per month per disease state over patients, and (iii)
multiplying this overall mean result by 12 and by the vial
unit costs of ERT (see Table 2 for the latter). Table 3
shows the mean yearly ERT costs by disease state.
The costs of AMC hospital care were calculated by
taking the product sum of hospital resources used and
their respective unit costs. The costs were averaged per
patient (both treated and untreated) per disease state per
year of follow-up, and subsequently per disease state
over patients to get the mean yearly AMC costs per dis-
ease stage (Table 4).
Table 1 Mean health utility by disease state
Disease state N* Health utility
UK 95% LCL 95% UCL NL 95% LCL 95% UCL
Asymptomatic ** 0.93 0.8900 0.9700 0.93 0.8900 0.9700
Symptoms/recovery 17 0.8716 0.8177 0.9225 0.8897 0.8410 0.9349
Splenectomy 4 0.7532 0.6768 0.8215 0.7781 0.6990 0.8626
Bone complication 6 0.8614 0.7530 0.9685 0.8882 0.8027 0.9707
Multiple complications 13 0.7323 0.6601 0.8202 0.7981 0.7430 0.8638
Malignancy 1# 0.15 0.364
LCL: lower limit of the confidence interval, UCL: upper limit of the confidence interval.
*Patients may contribute to more than one disease state.
**We used a foreign estimate of 0.93 (95% CI: 0.89-0.97) for healthy persons reported by Clarke et al. [16]. This estimate too was based on time trade-off based
elicitation techniques.
#The observed estimate for the stage of malignancy was based on just 1 person, but well within the range of values expected for end-stage malignant disease
(e.g. Brown et al. [17]).
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resources as derived 3-monthly from the Health and
Labour questionnaires were averaged per patient per
disease state independently from treatment status, multi-
plied by 4 to arrive at yearly mean estimates per patient
per disease state, and then averaged per disease state
over patients. Table 5 shows the mean yearly volumes
and costs of out-of-hospital consultations by disease
state, of which the mean total values are included in the
Markov model.
For 70.5 person-years of questionnaire data on health
care use in hospitals other than the AMC as tertiary
referral centre only 33 inpatient hospital days were
reported, equivalent to about €15,000 in total. For theTable 2 Dutch unit costs (€) for resources used
Resource Unit costs
Inpatient hospital day 59
In-hospital day-care treatment 27
Enzyme replacement therapy per vial of 400 IU
Splenectomy
Other diagnostic and therapeutic procedures V








Productivity loss per hour^
#In case of different base years the general price index figures from the Dutch costi
the AMC hospital ledger for Gaucher patients include the costs of top referent heal
of visits over psychiatrists (€103) and psychologists (€80) respectively. ††Out-of-hosp
caregivers, i.e. the occupational physician. †††The Nederlandse Mededingings Autoritei
considerably, depending on the type of alternative healer. As a proxy, the reported un
advised 2000 tariff for an acupuncturist. ^Overall mean unit costs per hour, irrespectivmodel these costs were considered trivial. Likewise the
total costs of self-reported, prescribed medications other
than ERT during these person-years - €4,433 - seemed
redundant and have been discarded as well.
Table 6 shows the mean yearly costs of production loss
resulting from sick leave and (permanent) work disability
as a consequence of GD I. The costs for production loss
follow the human capital costing approach and were
derived in successive calculation steps. For each patient
with paid work the mean number of working hours per
day and the mean number of working hours per week
were derived from the Health and Labour questionnaire.
The mean volume of sick leave in number of days
per 2-week period was calculated per patient per diseasein 2009 euros# Source
6-1,036 AMC hospital ledger##
4 - 845 AMC hospital ledger
1,985 Dutch College of health care insurance
6,022 AMC hospital ledger
arious AMC hospital ledger
- 460 AMC hospital ledger
28 Dutch costing manual
36 Dutch costing manual
91.5 Dutch costing manual
26 AMC hospital ledger
65 Dutch costing manual
60 Expert opinion†††
30 Dutch costing manual
ng manual 2010 have been used to derive 2009 estimates. ##Unit costs from
th care. †Weighted unit cost based on the assumption of 50%-50% distribution
ital visit to other care givers are assigned the lowest unit costs among the
t prohibits the use of an advised tariff. Unit costs per consultation may vary
it cost of 60 euro per visit is based on an indexed derivation of the
e of gender, age, and occupation.
Table 3 Mean yearly volume and costs of enzyme replacement therapy by disease state
Disease state N* Number of vials 95% LCL 95% UCL Costs 95% UCL 95% UCL
Signs/symptoms 28 76 62 91 151,147 123,501 180,088
Recovery 19 63 49 75 124,183 97,529 149,041
Splenectomy 6 78 50 111 155,082 98,443 220,004
Bone complication 9 102 75 132 202,348 149,319 261,573
Multiple complications 18 86 70 102 170,317 138,201 202,653
Malignancy 5 130 68 209 257,469 135,582 414,084
LCL: lower limit of the confidence interval, UCL: upper limit of the confidence interval.
*Patients may contribute to more than one disease state.
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This volume was then multiplied by 26 and by the overall
mean number of working hours per day to arrive at the
yearly mean production loss per patient with paid work
per disease state. For patients with (permanent) work
disability because of GD I the estimated yearly volume of
production loss was based on the overall mean number
of working hours per working day and overall mean
number of working days per week for patients with paid
work. For patients who did not have paid work for
reasons other than GD I a zero volume of production
loss was assumed.
The calculated or defined yearly volume of production
loss in hours per patient per disease state was multiplied
by the average unit cost per hour of production loss
irrespective of the gender or age of the patient (€30, see
Table 2). Subsequently these costs were averaged per
disease state over patients.
Analysis
The model was run from a lifetime perspective, starting
asymptomatically at birth until the age of 85 years or
until death. Hypothetical cohorts of treated and untreated
patients in the Markov model were compared for the
primary outcome parameters of the cost-effectiveness
and cost-utility analyses by dividing the lifetime costs
difference by the difference in lifetime years free ofTable 4 Mean yearly numbers and costs of diagnostic and the
Disease state** Mean costs per procedure in € Num
proce
Asymptomatic (N = 4) 20.9 7
Signs/symptoms (N = 25) 33.5 8
Recovery (N = 20) 32.4 9
Splenectomy (N = 5) 35.4 13
Bone complication (N = 8 40.9 10
Multiple complications (N = 22) 24.0 9
Malignancy (N = 4) 76.4 36
LCL: lower limit of the confidence interval, UCL: upper limit of the confidence interv
*AMC inpatient days too were counted as procedures here.
**Patients may contribute to more than one disease state.end-organ damage or by the difference in lifetime QALYs
respectively.
In the base case scenario, patients entered the model
at birth; ERT was initiated when signs/symptoms devel-
oped; the costs only included the medical costs; no
discounting of effects or costs was performed. Sensitivity
analyses have been performed concerning the choice of
discount rate (discounting of effects by 1.5% and costs
by 4% instead of no discounting for both) [20] and for
the Dutch instead of the UK time trade-off based health
utility algorithm. Considering that we assumed equal
health utilities and costs (excluding ERT medication) for
treated and untreated patients during the same disease
states, we put most emphasis on assessing the impact of
parameter uncertainty resulting from the transition
probabilities from one disease state to the next. To
this end, a Monte Carlo simulation was performed
with 1,000 second-order draws from the beta-distributed
yearly transition probabilities in the Markov model to
represent parameter uncertainty with each single draw
including 100 first-order trials to represent patient
heterogeneity. Additionally, the impact of parameter
uncertainty concerning the health utility and costs esti-
mates were assessed assuming triangular distributions
(with mean estimates taken as the most likely values
and the 95% confidence limits taken as the minimum
and maximum values).rapeutic procedures* in the AMC by disease state
ber of
dures
95% LCL 95% UCL Costs in € 95% LCL 95% UCL
0.2 25.0 102.4 1,470 455 2,152
6.1 63.5 110.5 2,887 1,974 3,885
4.3 79.6 110.1 3,055 1,708 4,858
6.6 106.8 171.1 4,836 2,544 7,145
6.0 73.9 154.9 4,337 1,590 9,313
1.3 75.2 109.8 2,194 1,652 2,826
0.1 68.0 646.3 27,523 4,786 51,722
al.
Table 5 Mean yearly numbers and costs of out-of-hospital consultations§ by disease state
Disease state* Volumes 95% LCL 95% UCL Costs in € 95% LCL 95% UCL
(No) signs/symptoms (N = 10)** 3.6 1.1 7.8 121 31 272
Recovery (N = 9) 16.8 6.3 28.3 641 229 1,097
Splenectomy (N = 4) 6.0 0.3 11.6 299 8 589
Bone complication (N = 6) 12.7 1.6 26.4 449 51 939
Multiple complications (N = 13) 6.8 2.9 11.2 245 97 421
Malignancy (N = 1) 2 56
LCL: lower limit of the confidence interval, UCL: upper limit of the confidence interval.
*Patients may contribute to more than one disease state. **Data from two asymptomatic patients have been added to data from eight symptomatic patients to
improve precision; the estimates were applied to both, the asymptomatic as well as symptomatic Markov disease state. § Patients in the asymptomatic and
symptomatic disease states reported visiting the general physician, physiotherapist, company physician, and alternative healer. Patients in recovery reported
visiting the general physician, physiotherapist, social worker, and alternative healer. Patients with a splenectomy reported visiting the general physician, social
worker, and alternative healer. Patients with a bone complication reported visiting the general physician, physiotherapist, and company physician. Patients with
multiple complications reported visiting the general physician, physiotherapist, psychologist/psychiatrist, company physician, social worker, and alternative healer.
The patient with a malignancy reported visiting the general physician.
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gained by ERT versus standard medical care are reported
as a cost-effectiveness plane and as a cost-effectiveness
acceptability curve for willingness to pay (WTP) values
up to 10,000,000 euro per QALY.
Scenario analyses
Following the base case scenario we ran three alternative
scenarios:
– (a) adding the costs of production loss to
the medical costs, assuming a maximum
productive period of 40 years (between one’s
25th and 64th years of age).
– (b) reducing the costs of ERT by 25% to reflect
the actual (minus 15%) and perhaps potential
(minus another 10%) variation in costs per vial
– (c) taking the historical perspective by accounting
for the time that ERT first became available for
the Dutch market.Table 6 Mean yearly indirect costs of production loss by
disease state
Disease state N* Costs of production
loss in €**
95% LCL 95% UCL
Signs/symptoms 9 0 0 0
Recovery 9 0 0 0
Splenectomy 4 13,698 0 27,396
Bone complication 6 10,002 0 20,004
Multiple
complications
13 10,615 0 21,230
Malignancy 1 73,057
LCL: lower limit of the confidence interval, UCL: upper limit of the
confidence interval.
*Patients may contribute to more than one disease state.
**Based on the human capital valuation method. Volume data in number of
hours can be derived by dividing the cost figures by the unit cost per lost
working hour (or €30).Results
Health outcomes, medical costs, incremental
cost-effectiveness ratio, and cost-effectiveness acceptability
Under the base case scenario, GD I patients receiving
standard medical care generated 48.9 YFEOD and 55.86
QALYs during their lifetime. If treated with ERT, these
numbers increased to 61.7 YFEOD and 62.13 QALYs,
resulting in health gains of 12.8 YFEOD and 6.27 QALYs
respectively. Not treating Gaucher patients with ERT
resulted, on average, in €171,780 over a patient’s lifetime.
Treatment with ERT resulted in a mean lifetime costs of
€5,716,473, a difference of €5,544,693. The incremental
cost-effectiveness ratios of ERT treatment against stand-
ard medical care only equaled €434,416 per YFEOD and
€884,994 per QALY (Tables 7 and 8). Figure 2a shows
the incremental medical costs on the Y-axis against the
incremental QALYs on the X-axis of ERT treatment
against standard medical care after Monte Carlo simula-
tion of the transition probabilities in the Markov model.
Most simulations end up in the upper right quadrant
(96.3%), indicating increasing costs and QALYs. Figure 2b
shows the corresponding cost-effectiveness acceptability
curve with the probability of ERT being cost-effective on
the Y-axis for different WTP values on the X-axis. The
probability of ERT treatment being cost-effective equaled
0.25, 0.5 and 0.75 at WTP values of about €860,000,
€1,370,000, €2,360,000 per QALY respectively. These
latter results changed into about €850,000, €1,420,000,
€2,810,000 per QALY respectively when taking uncer-
tainties regarding health utilities and costs into account
as well (Figure 3a).
Discounting effects and costs and applying dutch general
population preferences for health states
After discounting of effects by 1.5% yearly, GD I patients
receiving standard medical care generated 31.97 YFEOD
and 34.65 QALYs during their lifetime, while patients on
Table 7 Incremental costs per year free of end organ damage gained under different scenarios, undiscounted
(upper rows) and discounted (lower rows)
Scenario YFEOD Costs ICER
ERT no ERT Δ ERT no ERT Δ
Base case 61.70 48.90 12.80 €5,716,473 €171,780 €5,544,693 €434,416
37.77 31.97 5.80 €1,206,933 €50,048 €1,156,885 €199,559
Production loss included 61.70 48.90 12.80 €5,772,897 €294,226 €5,478,670 €429,243
37.77 31.97 5.80 €1,216,954 €71,956 €1,144,998 €197,508
25% ERT costs reduction 61.70 48.90 12.80 €4,338,430 €171,780 €4,166,649 €326,449
37.77 31.97 5.80 €918,801 €50,048 €868,753 €149,857
Historical I* 19.72 17.90 1.82 €5,202,872 €109,342 €5,093,530 €2,803,382
14.83 13.70 1.14 €2,391,020 €54,143 €2,336,877 €2,057,891
Historical II* 12.10 10.14 1.96 €6,198,258 €112,774 €6,085,484 €3,111,478
9.27 8.01 1.26 €3,031,062 €59,253 €2,971,809 €2,363,665
YFEOD: years free of end organ damage, ICER: incremental cost-effectiveness ratio. *The historical scenarios were based on the patient distribution in the
Netherlands when ERT was introduced in April 1991 and were derived from medical histories of patients referred to the AMC until September 2011. The first
historical scenario includes the asymptomatic stage, the second historical scenario excludes the asymptomatic stage. While running the historical scenarios, two
model adjustments were made: 1) the probability of death was adjusted for the mean age of 36 (Historical I) or 38 (Historical II) years for patients in the cohort at
the time of ERT market introduction in the Netherlands; 2) the time horizon too was adjusted for the mean age of the cohort in 1991 and became 49 (Historical I)
or 47 (Historical II) years instead of 85.
€: amount of money in euros.
Δ: difference between between the scenarios with versus without ERT.
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counting of costs by 4% yearly, Gaucher patients not on
ERT treatment generated €50,048, while ERT patients
generated €1,206,933 during their lifetime. Discounting
decreased the incremental cost-effectiveness ratio from
€434,416 to €199,559 per YFEOD gained and from
€884,994 to €432,540 per QALY gained. Figure 3b shows
the cost-effectiveness acceptability of ERT against stand-
ard medical care following discounting, after Monte
Carlo simulation of all model parameters and forTable 8 *Incremental costs per quality adjusted life year gain
and discounted (lower rows)
Scenario QALY
ERT no ERT Δ
Base case 62.13 55.86 6.27
37.33 34.65 2.67
Production loss included 62.13 55.86 6.27
37.33 34.65 2.67
25% ERT costs reduction 62.13 55.86 6.27
37.33 34.65 2.67
Historical I 33.00 28.50 4.50
24.27 21.35 2.92
Historical II 30.28 24.65 5.64
22.52 18.78 3.74
QALY: quality adjusted life year, ICER: incremental cost-effectiveness ratio.
*For explanation of Historical I and Historical II, see notes Table 7.
€: amount of money in euros.
Δ: difference between between the scenarios with versus without ERT.different willingness to pay values per QALY. The prob-
ability of ERT treatment being cost-effective equaled
0.25, 0.5 and 0.75 at WTP values of about €400,000,
€690,000, €1,340,000 per QALY respectively.
Applying the Dutch general population preferences for
health status rather than the ones from the UK showed
slightly higher incremental costs per QALY ratios from
€884,994 per QALY to €918,709 per QALY undiscoun-
ted and €432,540 per QALY to €451,647 per QALY
discounted.ed under different scenarios, undiscounted (upper rows)
Costs ICER
ERT no ERT Δ
€5,716,473 €171,780 €5,544,693 €884,994
€1,206,933 €50,048 €1,156,885 €432,540
€5,772,897 €294,226 €5,478,670 €874,456
€1,216,954 €71,956 €1,144,998 €428,096
€4,338,430 €171,780 €4,166,649 €665,043
€918,801 €50,048 €868,753 €324,812
€5,202,872 €109,342 €5,093,530 €1,131,036
€2,391,020 €54,143 €2,336,877 €800,359
€6,198,258 €112,774 €6,085,484 €1,079,504
€3,031,062 €59,253 €2,971,809 €794,656
Figure 2 Enzyme replacement therapy against standard medical therapy after Monte Carlo simulation of transition probabilities.
(A) Scatterplot of undiscounted incremental medical costs and QALYs (B) corresponding cost-effectiveness acceptability curve.
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The undiscounted and discounted results from the scenario
analyses with YFEOD and QALYs as the primary clinical
outcomes are reported in Tables 7 and 8 respectively.
The Tables show that including the costs of production
loss resulted in marginally lower incremental costs per
YFEOD (minus €5,173 undiscounted; minus €2,051 dis-
counted) and incremental costs per QALY (minus €10,538
undiscounted; minus €4,444discounted) in comparison with
the base case scenarios. Reduction of the costs of ERT sub-
stantially decreased the undiscounted incremental costs per
YFEOD from €434,416 to €326,449 (discounted from
€199,559 to €149,857) and the undiscounted incremental
costs per QALY from €884,994 to €665,043 (discounted
from €432,540 to €324,812).
Both variants of the historical scenario were accompan-
ied by substantial increases of all the incremental cost-
effectiveness ratios.Figure 3 Cost-effectiveness acceptability curves for enzyme replacem
simulation of all model parameters. (A) Undiscounted (B) discounted.Discussion
Summary and significance of major findings
The modeling of ERT for GD I with a lifetime time horizon
of 85 years demonstrated important gains in effectiveness
with 12.8 extra years free of end-organ damage (discounted:
5.8) and 6.27 additional QALYs (discounted: 2.67). With
average yearly ERT medication costs easily ranging between
€124,000 and €258,000 from the moment signs/symptoms
develop, the extra lifetime costs of ERT compared with
standard medical care without ERT amounted to €5,544,693
per patient on average (discounted: €1,156,885), resulting
in incremental cost-effectiveness ratios of €434,416 per
YFEOD (discounted: €199,559) and €884,994 per QALY
(discounted: €432,540). The acceptability of ERT for GD I
may top a high 96% from a health economic perspective,
but this obviously will depend on society’s willingness to
pay per QALY. Given current standards for affordable
health care interventions, these results may leave theent therapy against standard medical care after Monte Carlo
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under continuing debate. However, there are some study
limitations (see below) that forced us to take a conserva-
tive stand while quantifying model parameters. This, in
turn, necessarily qualifies the major findings as conserva-
tive ones.
The societal perspective of this economic evaluation is
dominated by the health care costs. Adding the costs of
production loss based on a human capital approach, i.e.
taking all current and future production loss resulting
from sick leave and work disability into account, only
marginally changed the major findings for the better
(lower incremental cost-effectiveness ratios). The appli-
cation of the (nationally advised) friction cost method to
the costing of production loss - resulting from sick leave
and less productivity while at work - would have resulted
in even smaller changes and has justifiably not received
further attention here.
Both historical scenarios reflecting relatively delayed
starts of ERT when patients in a population already are
in various stages of the disease at the time of its market
introduction showed worse off incremental cost-effective-
ness ratios compared to the base case scenario. This indi-
cates that starting ERT right when patients are in need of
it in an early signs/symptomatic stage, is probably the
most sensible approach, both from a medical as well as
health economic perspective.
One should further note that the significance of ERT
provision for the national health care budget is not just
a matter of costs per QALY gained, but also a matter of
demand for health care, which is low here given that
Gaucher disease is rare. Whether society is willing to
pay more for treatments of rare disorders than for more
prevalent diseases is uncertain. This discussion can only
be started once cost-effectiveness analyses are carried
out and costs per QALY are known.
Study limitations
Important limitations of this ERT evaluation study
include the small size of the studied cohort and the non-
randomized, partly retrospective study design. Simplifi-
cations of the model structure that reflects the course of
the Gaucher disease and making assumptions during
data analysis and estimation of model parameters were
needed to exert as much control as possible over factors
other the enzyme replacement therapy itself that may
explain differences in model outcomes between treated
and untreated patient cohorts.
To contain possible distortions due to ‘confounding by
indication’ and obtain an adequate description of the
natural course of Gaucher disease when most Gaucher
patients actually already receive ERT, we obtained all
data on the natural course of disease progression retro-
spectively from patient records before the era of ERT.However, data on signs/symptoms and complications
might not have been recorded as rigorously as would
have been the case in a prospectively designed study.
We therefore cannot exclude the possibility that the rate
of disease progression in untreated patients has been
underestimated in the present analysis.
At the same time, transition probabilities for disease
progression among patients receiving ERT have probably
been overestimated, because an accurate set of patients
starting on treatment in an early signs/symptomatic
stage could not be identified without a considerable risk
of selection bias by overrepresentation of patients who
progress slowly. The reported base case scenario approx-
imates the ideal scenario for upcoming Gaucher cases,
because the transition probabilities used in that scenario
partly reflect delayed start of therapy in various disease
stages. As a result, we have perhaps underestimated the
full potential of ERT.
Another limitation of our study concerns the world-
wide imiglucerase shortage. Questionnaires to assess
quality of life were distributed from June 2009 onwards
which coincides with the period of shortage. One might
argue that the shortage could have had an impact on the
quality of life of patients. However, based on the litera-
ture discussing the impact of the shortage on patients’
well being [21,22], this effect is assumed to be small.
Finally, ERT dose and frequency of ERT administration
differ between countries, which may impact transferabil-
ity of these results to other countries. ERT regimen will
influence costs of treatment and may influence disease
course. Nonetheless, a comparison between AMC data
and literature data, details of which are reported in the
appendix, revealed that data used in our model of
disease course are in line with results reported in the
literature.
Implications and recommendations for future studies
Although this study on Gaucher disease shows an 7-fold
more favorable cost-effectiveness ratio when compared
to a recently accomplished similar analysis for Fabry dis-
ease [7], costs per QALY are well above what is generally
perceived as affordable. In case of Gaucher disease, not
meeting the cost-effectiveness limits (for non-rare diseases)
is clearly not resulting from a lack of effectiveness of the
ERT with almost 13 years free of end-organ damage for
each individual patient. We plea for lowering the unit costs
of ERT and making these unit costs negotiable in public-
private partnerships that incorporate some risk coverage
for pharmaceutical companies with highly promising,
‘priceless’ drugs for rare diseases in their portfolio. En-
zyme replacement therapy for Gaucher disease seems one
of them.
In addition, the outcomes of the current study can fuel
the debate on drug pricing as we show that price drops
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per QALY ratio. In addition, as ERT for GD I is widely
implemented and reimbursement guaranteed in most
Western countries during more than 20 years, the
current analysis may also serve as a benchmark for dis-
cussions on orphan drug price limits. We suggest that
the excellent effectiveness and safety of ERT has contrib-
uted importantly to this situation.
An important lesson is to be learned from the limita-
tions cited for our study. Sufficient and reliable data on
the natural course of a disease are essential not only to
assess the effectiveness of future treatments, but also
from a cost-effectiveness perspective. It has become
clear that studies are mostly restricted to uncontrolled
trials or observational studies after a certain drug has
become registered. This is specifically the case when
registration took place under ‘exceptional circumstances’,
meaning that additional clinical trial data will probably
not become available during the post-marketing autho-
rization period. Therefore we argue for the systematic
collection of natural history data, within a disease regis-
try rather than a company sponsored drug registry [23],
aiming to obtain the relevant data that are needed to
perform adequate efficacy but also cost-effectiveness
analyses. Otherwise, such analyses will be permanently
hampered by shortcomings as reported in this paper.Endnote
aPlease note that the base case scenario relates to sce-
nario B in the companion paper on Long term enzyme
replacement therapy for Gaucher disease, while the his-
torical scenario relates to scenario A in that paper.Additional file
Additional file 1: Gaucher Model Appendix.Competing interest
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